The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Adult Non-Hodgkin Lymphoma Treatment Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Adult Non-Hodgkin Lymphoma Treatment Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publishing Date : Aug, 2023

License Type :
 

Report Code : 1773591

No of Pages : 108

Ask Your Query

Synopsis
The global Adult Non-Hodgkin Lymphoma Treatment market size was valued at USD 7820 million in 2022 and is forecast to a readjusted size of USD 13440 million by 2029 with a CAGR of 8.0% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Non-Hodgkin lymphoma (NHL) is an umbrella term for a group of independent diseases with strong heterogeneity
This report is a detailed and comprehensive analysis for global Adult Non-Hodgkin Lymphoma Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global Adult Non-Hodgkin Lymphoma Treatment market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Adult Non-Hodgkin Lymphoma Treatment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Adult Non-Hodgkin Lymphoma Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Adult Non-Hodgkin Lymphoma Treatment market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for Adult Non-Hodgkin Lymphoma Treatment
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace

This report profiles key players in the global Adult Non-Hodgkin Lymphoma Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

Key companies covered as a part of this study include Janssen Pharma, Genentech, Inc., CELGENE CORPORATION, Merck & Co.,Inc. and Kyowa Kirin Co., Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Adult Non-Hodgkin Lymphoma Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • B Cell
  • T Cell
  • NK/T Cells

Market segment by Application

  • Hospital
  • Clinic

Major players covered

  • Janssen Pharma
  • Genentech, Inc.
  • CELGENE CORPORATION
  • Merck & Co.,Inc.
  • Kyowa Kirin Co., Ltd.
  • AbbVie Inc.
  • Sanofi
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • Bayer AGNovartis AG
  • Kite Pharma, Inc
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical lndustries Ltd.
  • Bristol Myers Squibb Company

Market segment by region, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Adult Non-Hodgkin Lymphoma Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adult Non-Hodgkin Lymphoma Treatment, with price, sales, revenue and global market share of Adult Non-Hodgkin Lymphoma Treatment from 2018 to 2023.
Chapter 3, the Adult Non-Hodgkin Lymphoma Treatment competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adult Non-Hodgkin Lymphoma Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adult Non-Hodgkin Lymphoma Treatment market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adult Non-Hodgkin Lymphoma Treatment.
Chapter 14 and 15, to describe Adult Non-Hodgkin Lymphoma Treatment sales channel, distributors, customers, research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Adult Non-Hodgkin Lymphoma Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 B Cell
1.3.3 T Cell
1.3.4 NK/T Cells
1.4 Market Analysis by Application
1.4.1 Overview: Global Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Adult Non-Hodgkin Lymphoma Treatment Market Size & Forecast
1.5.1 Global Adult Non-Hodgkin Lymphoma Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adult Non-Hodgkin Lymphoma Treatment Sales Quantity (2018-2029)
1.5.3 Global Adult Non-Hodgkin Lymphoma Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Janssen Pharma
2.1.1 Janssen Pharma Details
2.1.2 Janssen Pharma Major Business
2.1.3 Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.1.4 Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Janssen Pharma Recent Developments/Updates
2.2 Genentech, Inc.
2.2.1 Genentech, Inc. Details
2.2.2 Genentech, Inc. Major Business
2.2.3 Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.2.4 Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Genentech, Inc. Recent Developments/Updates
2.3 CELGENE CORPORATION
2.3.1 CELGENE CORPORATION Details
2.3.2 CELGENE CORPORATION Major Business
2.3.3 CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.3.4 CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 CELGENE CORPORATION Recent Developments/Updates
2.4 Merck & Co.,Inc.
2.4.1 Merck & Co.,Inc. Details
2.4.2 Merck & Co.,Inc. Major Business
2.4.3 Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.4.4 Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck & Co.,Inc. Recent Developments/Updates
2.5 Kyowa Kirin Co., Ltd.
2.5.1 Kyowa Kirin Co., Ltd. Details
2.5.2 Kyowa Kirin Co., Ltd. Major Business
2.5.3 Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.5.4 Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Kyowa Kirin Co., Ltd. Recent Developments/Updates
2.6 AbbVie Inc.
2.6.1 AbbVie Inc. Details
2.6.2 AbbVie Inc. Major Business
2.6.3 AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.6.4 AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AbbVie Inc. Recent Developments/Updates
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.7.4 Sanofi Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Sanofi Recent Developments/Updates
2.8 Takeda Pharmaceutical Company
2.8.1 Takeda Pharmaceutical Company Details
2.8.2 Takeda Pharmaceutical Company Major Business
2.8.3 Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.8.4 Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Takeda Pharmaceutical Company Recent Developments/Updates
2.9 AstraZeneca
2.9.1 AstraZeneca Details
2.9.2 AstraZeneca Major Business
2.9.3 AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.9.4 AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 AstraZeneca Recent Developments/Updates
2.10 Bayer AGNovartis AG
2.10.1 Bayer AGNovartis AG Details
2.10.2 Bayer AGNovartis AG Major Business
2.10.3 Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.10.4 Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bayer AGNovartis AG Recent Developments/Updates
2.11 Kite Pharma, Inc
2.11.1 Kite Pharma, Inc Details
2.11.2 Kite Pharma, Inc Major Business
2.11.3 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.11.4 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Kite Pharma, Inc Recent Developments/Updates
2.12 Spectrum Pharmaceuticals, Inc.
2.12.1 Spectrum Pharmaceuticals, Inc. Details
2.12.2 Spectrum Pharmaceuticals, Inc. Major Business
2.12.3 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.12.4 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments/Updates
2.13 Teva Pharmaceutical lndustries Ltd.
2.13.1 Teva Pharmaceutical lndustries Ltd. Details
2.13.2 Teva Pharmaceutical lndustries Ltd. Major Business
2.13.3 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.13.4 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Teva Pharmaceutical lndustries Ltd. Recent Developments/Updates
2.14 Bristol Myers Squibb Company
2.14.1 Bristol Myers Squibb Company Details
2.14.2 Bristol Myers Squibb Company Major Business
2.14.3 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Product and Services
2.14.4 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Bristol Myers Squibb Company Recent Developments/Updates
3 Competitive Environment: Adult Non-Hodgkin Lymphoma Treatment by Manufacturer
3.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Adult Non-Hodgkin Lymphoma Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adult Non-Hodgkin Lymphoma Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adult Non-Hodgkin Lymphoma Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Adult Non-Hodgkin Lymphoma Treatment Manufacturer Market Share in 2022
3.5 Adult Non-Hodgkin Lymphoma Treatment Market: Overall Company Footprint Analysis
3.5.1 Adult Non-Hodgkin Lymphoma Treatment Market: Region Footprint
3.5.2 Adult Non-Hodgkin Lymphoma Treatment Market: Company Product Type Footprint
3.5.3 Adult Non-Hodgkin Lymphoma Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Adult Non-Hodgkin Lymphoma Treatment Market Size by Region
4.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Adult Non-Hodgkin Lymphoma Treatment Average Price by Region (2018-2029)
4.2 North America Adult Non-Hodgkin Lymphoma Treatment Consumption Value (2018-2029)
4.3 Europe Adult Non-Hodgkin Lymphoma Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Adult Non-Hodgkin Lymphoma Treatment Consumption Value (2018-2029)
4.5 South America Adult Non-Hodgkin Lymphoma Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Adult Non-Hodgkin Lymphoma Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Type (2018-2029)
5.2 Global Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Type (2018-2029)
5.3 Global Adult Non-Hodgkin Lymphoma Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Application (2018-2029)
6.2 Global Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Application (2018-2029)
6.3 Global Adult Non-Hodgkin Lymphoma Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Type (2018-2029)
7.2 North America Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Application (2018-2029)
7.3 North America Adult Non-Hodgkin Lymphoma Treatment Market Size by Country
7.3.1 North America Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Adult Non-Hodgkin Lymphoma Treatment Market Size by Country
8.3.1 Europe Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adult Non-Hodgkin Lymphoma Treatment Market Size by Region
9.3.1 Asia-Pacific Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Type (2018-2029)
10.2 South America Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Application (2018-2029)
10.3 South America Adult Non-Hodgkin Lymphoma Treatment Market Size by Country
10.3.1 South America Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Market Size by Country
11.3.1 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Adult Non-Hodgkin Lymphoma Treatment Market Drivers
12.2 Adult Non-Hodgkin Lymphoma Treatment Market Restraints
12.3 Adult Non-Hodgkin Lymphoma Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Adult Non-Hodgkin Lymphoma Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adult Non-Hodgkin Lymphoma Treatment
13.3 Adult Non-Hodgkin Lymphoma Treatment Production Process
13.4 Adult Non-Hodgkin Lymphoma Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adult Non-Hodgkin Lymphoma Treatment Typical Distributors
14.3 Adult Non-Hodgkin Lymphoma Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock